StockGlow

Voyager Therapeutics, Inc. (VYGR)

Develops gene therapies to treat neurological diseases like Alzheimer's and Huntington's.

$3.04-0.02%Healthcare
Compare VYGR with
StockGlow Score
53
Neutral
BearishBullish
1 year ago+2.7%

The outlook

Voyager Therapeutics trades near its 52-week low at $3.04, well below both its 50- and 200-day moving averages. Analysts are unanimously bullish with a "Strong Buy" consensus and an average price target suggesting 390% upside from current levels. The stock's technical position remains weak despite strong analyst sentiment.

What’s behind the score

Analyst consensusStrong Buy — 1.0 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Price targetAvg target +390% vs current price

Analyst price target

~12-month · 9 analysts
$14.89average target+389.8% vs now
Now $3.04
Low $8.00High $25.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$183.7M
52-wk high
$5.55
52-wk low
$2.88
50-day avg
$3.53
200-day avg
$3.97
Trailing P/E
—

Similar stocks

RGNXREGENXBIO Inc.$9.60-1.13%SLDBSolid Biosciences Inc.$7.97+1.01%QUREuniQure N.V.$36.66-4.06%MGTXMeiraGTx Holdings plc$11.82-3.90%CTMXCytomX Therapeutics, Inc.$3.22-0.92%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy